Delivery Order SPE2DB24D3015-SPE2DB25FGAQL
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,325.02 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets in quantities of 30-count units. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, ultimately due for completion on August 19, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order represents a child contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) valued at $9,027.48 under a firm fixed-price contract type. The award was issued on July 28, 2025, with an ultimate completion date of July 29, 2025, and was competitively awarded with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs,...
- The Defense Logistics Agency awarded a delivery order valued at $1,632.60 to AmerisourceBergen Drug Corp for XELJANZ XR 11 MG tablets (30-count units) on August 5, 2025, with completion scheduled for August 6, 2025. This firm fixed-price delivery order represents a non-competitive award under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp, headquartered in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,198.50 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 mg tablets (30-count units). This firm fixed price, non-set-aside delivery order was awarded on August 20, 2025, with an ultimate completion date of August 21, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. XELJANZ XR is a prescription immunosuppressant medication used to treat rheumatoid arthritis...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,012.98 to AmerisourceBergen Drug Corp for the supply of XELJANZ 5 MG tablets (60-count units). This competitively awarded, firm fixed-price contract with no set-aside designation was issued on August 11, 2025, with an ultimate completion date of August 12, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,599.24 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count unit of use packaging) under a firm fixed price contract type. This delivery order, awarded on July 31, 2025, with an ultimate completion date of August 1, 2025, represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. XELJANZ XR...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $20,578.74 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) under a firm fixed-price contract type. The award was made on August 4, 2025, with an ultimate completion date of August 5, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, performed the work at its corporate office location and serves as a critical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,401.41 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 MG tablets in quantity 30s. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, completed on July 28, 2025. The contract was issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1 billion global pharmaceutical support vehicle that runs...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. This firm fixed-price delivery order, valued at $11,275.80, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The contract was competitively awarded with no set-aside designation and is scheduled for completion by August 13, 2025. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $15,418.01 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 MG tablets in quantities of 30 units. This competitively awarded, firm fixed price delivery order is set to be completed by July 25, 2025, and represents a non-set-aside procurement. The award was issued on July 24, 2025, with performance taking place at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued...
- SPE2DB24D3015Indefinite Delivery Contract
- SPE2DB24D3015-SPE2DB25FGAQLDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,535.33 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 mg tablets (30-count units). This firm fixed-price, competitively awarded contract was executed on August 19, 2025, with an ultimate completion date of August 20, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as a comprehensive pharmaceutical supply vehicle supporting military healthcare programs globally. XELJANZ XR is a branded immunosuppressant medication used in the treatment of rheumatoid arthritis and other autoimmune conditions, representing the type of specialty pharmaceutical products that AmerisourceBergen routinely delivers through its DLA prime vendor contracts. As a major pharmaceutical distributor and critical federal vendor, AmerisourceBergen holds a significant position within the Defense Health Agency's medical supply chain, providing a broad portfolio of brand-name and generic medications, vaccines, and medical supplies to support military healthcare requirements. The DLA's Pharmaceutical Prime Vendor program leverages such indefinite delivery contracts to ensure reliable access to essential medications for military personnel and veteran populations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.5k | 8/19/25 |